Gordon R Bernard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10793558/publications.pdf Version: 2024-02-01

	8732	24915
74,880	75	109
citations	h-index	g-index
112	112	10060
115	115	40000
docs citations	times ranked	citing authors
	74,880 citations 113 docs citations	74,880 citations 75 h-index 113 docs citations

#	Article	IF	CITATIONS
1	The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA - Journal of the American Medical Association, 2016, 315, 801.	3.8	16,554
2	Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. New England Journal of Medicine, 2001, 344, 699-709.	13.9	8,411
3	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Medicine, 2017, 43, 304-377.	3.9	4,590
4	Comparison of Two Fluid-Management Strategies in Acute Lung Injury. New England Journal of Medicine, 2006, 354, 2564-2575.	13.9	3,821
5	Multiple Organ Dysfunction Score. Critical Care Medicine, 1995, 23, 1638-1652.	0.4	3,338
6	Evaluation of delirium in critically ill patients: Validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Critical Care Medicine, 2001, 29, 1370-1379.	0.4	2,549
7	Delirium in Mechanically Ventilated Patients. JAMA - Journal of the American Medical Association, 2001, 286, 2703.	3.8	2,449
8	Delirium as a Predictor of Mortality in Mechanically Ventilated Patients in the Intensive Care Unit. JAMA - Journal of the American Medical Association, 2004, 291, 1753.	3.8	2,441
9	Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet, The, 2008, 371, 126-134.	6.3	2,434
10	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Critical Care Medicine, 2017, 45, 486-552.	0.4	2,336
11	Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. Critical Care Medicine, 2010, 38, 1513-1520.	0.4	1,501
12	Monitoring Sedation Status Over Time in ICU Patients. JAMA - Journal of the American Medical Association, 2003, 289, 2983.	3.8	1,314
13	Effect of Sedation With Dexmedetomidine vs Lorazepam on Acute Brain Dysfunction in Mechanically Ventilated Patients. JAMA - Journal of the American Medical Association, 2007, 298, 2644.	3.8	1,218
14	Comparison of the Sp o 2 /F io 2 Ratio and the Pa o 2 /F io 2 Ratio in Patients With Acute Lung Injury or ARDS. Chest, 2007, 132, 410-417.	0.4	1,140
15	Lorazepam Is an Independent Risk Factor for Transitioning to Delirium in Intensive Care Unit Patients. Anesthesiology, 2006, 104, 21-26.	1.3	1,102
16	Treating Patients with Severe Sepsis. New England Journal of Medicine, 1999, 340, 207-214.	13.9	1,021
17	Balanced Crystalloids versus Saline in Critically III Adults. New England Journal of Medicine, 2018, 378, 829-839.	13.9	969
18	Pulmonary-Artery versus Central Venous Catheter to Guide Treatment of Acute Lung Injury. New England Journal of Medicine, 2006, 354, 2213-2224.	13.9	948

#	Article	IF	CITATIONS
19	High-Dose Corticosteroids in Patients with the Adult Respiratory Distress Syndrome. New England Journal of Medicine, 1987, 317, 1565-1570.	13.9	893
20	The Effects of Ibuprofen on the Physiology and Survival of Patients with Sepsis. New England Journal of Medicine, 1997, 336, 912-918.	13.9	831
21	Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet, The, 2007, 369, 1553-1564.	6.3	802
22	Costs associated with delirium in mechanically ventilated patients*. Critical Care Medicine, 2004, 32, 955-962.	0.4	766
23	Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury*. Critical Care Medicine, 2002, 30, 2175-2182.	0.4	604
24	Depression, post-traumatic stress disorder, and functional disability in survivors of critical illness in the BRAIN-ICU study: a longitudinal cohort study. Lancet Respiratory Medicine,the, 2014, 2, 369-379.	5.2	487
25	Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Critical Care Medicine, 2002, 30, 1772-1777.	0.4	462
26	A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*. Critical Care Medicine, 2013, 41, 2069-2079.	0.4	423
27	A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*. Critical Care Medicine, 2010, 38, 1685-1694.	0.4	412
28	Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: The MIND randomized, placebo-controlled trial*. Critical Care Medicine, 2010, 38, 428-437.	0.4	403
29	A Trial of Antioxidants N-acetylcysteine and Procysteine in ARDS. Chest, 1997, 112, 164-172.	0.4	393
30	Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. New England Journal of Medicine, 2018, 379, 2506-2516.	13.9	390
31	Current opinions regarding the importance, diagnosis, and management of delirium in the intensive care unit: A survey of 912 healthcare professionals*. Critical Care Medicine, 2004, 32, 106-112.	0.4	385
32	Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*. Critical Care Medicine, 2005, 33, 2266-2277.	0.4	368
33	Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*. Critical Care Medicine, 2003, 31, 834-840.	0.4	359
34	Randomized trial of initial trophic versus full-energy enteral nutrition in mechanically ventilated patients with acute respiratory failure. Critical Care Medicine, 2011, 39, 967-974.	0.4	307
35	Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Critical Care Medicine, 2003, 31, 12-19.	0.4	293
36	Effect of an Early Resuscitation Protocol on In-hospital Mortality Among Adults With Sepsis and Hypotension. JAMA - Journal of the American Medical Association, 2017, 318, 1233.	3.8	288

#	Article	IF	CITATIONS
37	Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Critical Care Medicine, 2001, 29, 2051-2059.	0.4	287
38	Prognostic and Pathogenetic Value of Combining Clinical and Biochemical Indices in Patients With Acute Lung Injury. Chest, 2010, 137, 288-296.	0.4	287
39	Delirium and sedation in the intensive care unit: Survey of behaviors and attitudes of 1384 healthcare professionals*. Critical Care Medicine, 2009, 37, 825-832.	0.4	285
40	Distinct Molecular Phenotypes of Direct vs Indirect ARDS in Single-Center and Multicenter Studies. Chest, 2015, 147, 1539-1548.	0.4	283
41	Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study. Lancet Respiratory Medicine,the, 2018, 6, 213-222.	5.2	280
42	Large-scale implementation of sedation and delirium monitoring in the intensive care unit: A report from two medical centers*. Critical Care Medicine, 2005, 33, 1199-1205.	0.4	257
43	Delirium in the ICU and Subsequent Long-Term Disability Among Survivors of Mechanical Ventilation*. Critical Care Medicine, 2014, 42, 369-377.	0.4	243
44	Risk factors for post-traumatic stress disorder symptoms following critical illness requiring mechanical ventilation: a prospective cohort study. Critical Care, 2007, 11, R28.	2.5	231
45	Long-term Cognitive and Psychological Outcomes in the Awakening and Breathing Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 183-191.	2.5	222
46	Frailty and Subsequent Disability and Mortality among Patients with Critical Illness. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 64-72.	2.5	219
47	A Simple Multiple System Organ Failure Scoring System Predicts Mortality of Patients Who Have Sepsis Syndrome. Chest, 1993, 104, 230-235.	0.4	218
48	Recovery Rate and Prognosis in Older Persons Who Develop Acute Lung Injury and the Acute Respiratory Distress Syndrome. Annals of Internal Medicine, 2002, 136, 25.	2.0	213
49	The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis *. Critical Care Medicine, 2004, 32, 2199-2206.	0.4	199
50	Extended Evaluation of Recombinant Human Activated Protein C United States Trial (ENHANCE US). Chest, 2004, 125, 2206-2216.	0.4	184
51	Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome*. Critical Care Medicine, 2011, 39, 1343-1350.	0.4	181
52	Mechanical Ventilation in ARDS. Chest, 2007, 131, 921-929.	0.4	178
53	Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 798-806.	2.5	169
54	Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis. JAMA - Journal of the American Medical Association, 2021, 325, 742.	3.8	168

#	Article	IF	CITATIONS
55	Changing pattern of organ dysfunction in early human sepsis is related to mortality. Critical Care Medicine, 2000, 28, 3405-3411.	0.4	167
56	Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated). Clinical Infectious Diseases, 2003, 37, 50-58.	2.9	167
57	Chlorhexidine Bathing and Health Care–Associated Infections. JAMA - Journal of the American Medical Association, 2015, 313, 369.	3.8	167
58	Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Medicine, 2003, 29, 894-903.	3.9	166
59	Simplified Severe Sepsis Protocol. Critical Care Medicine, 2014, 42, 2315-2324.	0.4	161
60	New strategies for clinical trials in patients with sepsis and septic shock. Critical Care Medicine, 2001, 29, 880-886.	0.4	157
61	Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis*. Critical Care Medicine, 2010, 38, 539-545.	0.4	157
62	Therapeutic Intervention and Targets for Sepsis. Annual Review of Medicine, 2005, 56, 225-248.	5.0	147
63	Atypical Sleep in Ventilated Patients. Critical Care Medicine, 2013, 41, 1958-1967.	0.4	140
64	Acute Lung Injury in Patients With Traumatic Injuries: Utility of a Panel of Biomarkers for Diagnosis and Pathogenesis. Journal of Trauma, 2010, 68, 1121-1127.	2.3	139
65	Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis. New England Journal of Medicine, 2021, 384, 1424-1436.	13.9	133
66	Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Critical Care, 2006, 10, R92.	2.5	116
67	Drotrecogin Alfa (Activated) Treatment of Older Patients with Severe Sepsis. Clinical Infectious Diseases, 2003, 37, 187-195.	2.9	111
68	Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Critical Care, 2003, 7, 155.	2.5	103
69	Consciousness monitoring in ventilated patients: bispectral EEG monitors arousal not delirium. Intensive Care Medicine, 2004, 30, 1537-1543.	3.9	101
70	Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Critical Care Medicine, 2003, 31, S85-S93.	0.4	100
71	Associations of markers of inflammation and coagulation with delirium during critical illness. Intensive Care Medicine, 2012, 38, 1965-1973.	3.9	93
72	Statins and Delirium During Critical Illness. Critical Care Medicine, 2014, 42, 1899-1909.	0.4	84

#	Article	IF	CITATIONS
73	The Role of the Coagulation Cascade in the Continuum of Sepsis and Acute Lung Injury and Acute Respiratory Distress Syndrome. Seminars in Respiratory and Critical Care Medicine, 2006, 27, 365-376.	0.8	79
74	Randomized, Placebo-Controlled Trial of Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis. Critical Care Medicine, 2015, 43, 534-541.	0.4	79
75	Effect of Bronchodilators on Lung Mechanics in the Acute Respiratory Distress Syndrome (ARDS). Chest, 1994, 106, 1517-1523.	0.4	73
76	Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsis*. Critical Care Medicine, 2004, 32, 2385-2391.	0.4	73
77	Diagnosis and therapy of acute respiratory distress syndrome in adults: An international survey. Journal of Critical Care, 1996, 11, 9-18.	1.0	71
78	Evaluating the Efficacy and Safety of Two Doses of the Polyclonal Anti-Tumor Necrosis Factor-α Fragment Antibody AZD9773 in Adult Patients With Severe Sepsis and/or Septic Shock. Critical Care Medicine, 2014, 42, 504-511.	0.4	70
79	A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome*. Critical Care Medicine, 2008, 36, 782-788.	0.4	68
80	Activated Protein C for Severe Sepsis. New England Journal of Medicine, 2002, 347, 1035-1036.	13.9	60
81	Impact of Initial Central Venous Pressure on Outcomes of Conservative Versus Liberal Fluid Management in Acute Respiratory Distress Syndrome. Critical Care Medicine, 2016, 44, 782-789.	0.4	57
82	The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) Protocol: a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. Trials, 2019, 20, 197.	0.7	57
83	ARDS Network (NHLBI) Studies: Successes and Challenges in ARDS Clinical Research. Critical Care Clinics, 2011, 27, 459-468.	1.0	51
84	The Role of Cyclooxygenase Products in Lung Injury Induced by Tumor Necrosis Factor in Sheep. The American Review of Respiratory Disease, 1992, 145, 632-639.	2.9	44
85	Quantification of organ dysfunction. Critical Care Medicine, 1998, 26, 1767-1768.	0.4	43
86	Identifying Clinical Research Priorities in Adult Pulmonary and Critical Care. NHLBI Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 511-523.	2.5	40
87	Identifying tweets of personal health experience through word embedding and LSTM neural network. BMC Bioinformatics, 2018, 19, 210.	1.2	33
88	Subsyndromal Delirium and Institutionalization Among Patients With Critical Illness. American Journal of Critical Care, 2017, 26, 447-455.	0.8	28
89	External validation of a biomarker and clinical prediction model for hospital mortality in acute respiratory distress syndrome. Intensive Care Medicine, 2017, 43, 1123-1131.	3.9	25
90	The Immune Response: Targets for the Treatment of Severe Sepsis. International Journal of Inflammation, 2012, 2012, 1-9.	0.9	16

#	Article	IF	CITATIONS
91	Protocolized Postextubation Respiratory Support to Prevent Reintubation: A Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 294-302.	2.5	15
92	Acute Lung Injury and the Acute Respiratory Distress Syndrome: Challenges in Clinical Trial Design. Clinics in Chest Medicine, 2006, 27, 733-754.	0.8	14
93	Vascular pedicle width in acute lung injury: correlation with intravascular pressures and ability to discriminate fluid status. Critical Care, 2011, 15, R86.	2.5	14
94	Relationship between Race and the Effect of Fluids on Long-term Mortality after Acute Respiratory Distress Syndrome. Secondary Analysis of the National Heart, Lung, and Blood Institute Fluid and Catheter Treatment Trial. Annals of the American Thoracic Society, 2017, 14, 1443-1449.	1.5	13
95	PEEP Guided by Esophageal Pressure — Any Added Value?. New England Journal of Medicine, 2008, 359, 2166-2168.	13.9	12
96	Drotrecogin Alfa (Activated) for the Treatment of Severe Sepsis and Septic Shock. American Journal of the Medical Sciences, 2004, 328, 205-214.	0.4	11
97	Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset Hypoxemia. Chest, 2022, 162, 804-814.	0.4	10
98	Revising Host Phenotypes of Sepsis Using Microbiology. Frontiers in Medicine, 2021, 8, 775511.	1.2	9
99	Measuring outcome differences associated with STEMI screening and diagnostic performance: a multicentred retrospective cohort study protocol. BMJ Open, 2018, 8, e022453.	0.8	7
100	Update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol: statistical analysis plan for a prospective, multicenter, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. Trials, 2019, 20, 670.	0.7	7
101	A Case Series of Drotrecogin Alfa (Activated) in Lung Transplant Recipients. Transplantation, 2006, 81, 1739-1742.	0.5	4
102	Protocolized Post-Extubation Respiratory Support to prevent reintubation: protocol and statistical analysis plan for a clinical trial. BMJ Open, 2019, 9, e030476.	0.8	4
103	Advances in sepsis treatment. Current Infectious Disease Reports, 2004, 6, 354-360.	1.3	3
104	CommLog: a communication log system for clinical trials. IEEE Transactions on Information Technology in Biomedicine, 2003, 7, 378-383.	3.6	2
105	A Data-Driven Method of Discovering Misspellings of Medication Names on Twitter. Studies in Health Technology and Informatics, 2018, 247, 136-140.	0.2	2
106	Identifying Consumer Health Terms of Side Effects in Twitter Posts. Studies in Health Technology and Informatics, 2018, 251, 273-276.	0.2	2
107	Extraction of Medication-Effect Relations in Twitter Data with Neural Embedding and Recurrent Neural Network. Studies in Health Technology and Informatics, 2022, , .	0.2	2
108	Giants in Chest Medicine. Chest, 2016, 149, 1126-1127.	0.4	0

0

#	Article	IF	CITATIONS
109	Research in Special Populations. , 2017, , 481-500.		0

Acute Illnesses, Critical Care, Emergency and Surgical Patients. , 2009, , 443-460.